Abstract: Here are described boroxine-containing compounds and their compositions for the treatment of wood. For instance, the treatment of wood includes its protection against moisture and/or degradation caused by insects or microbes.

Abstract: A bis(aryl)acetal has the formula wherein Y1 and Y2 are each independently chloro, bromo, iodo, mesylate, tosylate, triflate, or Bx, provided that Y1 and Y2 are not both selected from chloro, bromo, and iodo; each occurrence of Bx is independently a boron-containing functional group bonded to Ar1 or Ar2 via a boron atom; Ar1 and Ar2 are each independently unsubstituted or substituted C6-18 arylene, or unsubstituted or substituted C3-18 heteroarylene; provided that Ar1 and Ar2 are not covalently linked to each other to form a ring structure that includes —Ar1—O—C—O—Ar2—; and R1 and R2 are each independently hydrogen, unsubstituted or substituted C1-18 linear or branched alkyl, unsubstituted or substituted C3-20 cycloalkyl, unsubstituted or substituted C6-18 aryl, or unsubstituted or substituted C3-20 heteroaryl. The bis(aryl)acetal is useful as a monomer for oligoacetal and polyacetal synthesis via Suzuki polycondensation.

Abstract: This invention is related to compounds and/or compositions useful against pathogens affecting meats, plants, or plant parts. In one embodiment, the provided compounds are products of certain oxaborole moieties. In a further embodiment, the compound comprises a di-oxaborole compound. Delivery systems are also provided to take advantage of the volatile nature of these compounds and/or compositions.

Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.

Abstract: Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): and also from the novel intermediates having the formulae (1), (2), (3) and (10):

Abstract: The spectroscopic and photophysical properties of fluorescent probes comprising donor-acceptor derivatives comprising the boric acid group or a derivative of boric acid, B(OH)3 (or borate ion, BO(OH)2?1), arsenious acid, H3 AsO3 (or arsenite ion, H2AsO3?1), telluric acid, H6TeO6 (or tellurate ion, H5 TeO6?1) or germanic acid, Ge(OH)6 (or germanate ion, GeO(OH)3?1) are described. Method of using said probes are also provided.

Abstract: It comprises new substituted 4-valinylmethylphenyl boronic acids of formula (II) and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan (I) from such intermediates. The process comprises the reaction of the new 4-valinylmethylphenyl boronic compounds with a (halophenyl)tetrazole compound which proceeds with high yields. The process is particularly advantageous in its practical industrial realization because it avoids the use of azide derivatives and also the use of expensive biphenyl intermediates.

Abstract: A process for producing a ring-substituted arene borane which comprises reacting a ring-substituted arene with an HB organic compound in the presence of a catalytically effective amount of an iridium or rhodium complex with three or more substituents, excluding hydrogen, bonded to the iridium or rhodium and a phosphorus organic ligand, which is at least in part bonded to the iridium or rhodium, to form the ring-substituted arene borane. Also provided are catalytic compounds for catalyzing the process comprising an iridium or rhodium complex with three or substituents, excluding hydrogen, bonded to the iridium or rhodium and optionally, a phosphorus organic ligand, which is at least in part bonded to the iridium or rhodium.

Abstract: Disclosed are internally blocked borates useful for polymerizable compositions, and polymerizable adhesives made therewith. The internally blocked borates have general structures: wherein X represents —CHR6—, oxygen or sulfur; n is an integer; R1, R2, R3, R4, R5, and R6 are independently selected, for example, from unsubstituted and substituted C1-C10 alkyl, alkylene groups, or aryl groups, including other embodiments further defined, and M is a counter ion with positive charge m.

Abstract: Compounds, useful as protease inhibitors, of the formula (I): where: Ar is a ring or ring system, for example a benzene ring, and may be substituted by one or more moieties in addition to X and LJ; X is a functional group which is a hydrogen-bond acceptor, e.g. a nitro or boronate group BY1Y2; L is a linker, most preferably (CR5R6)—S—; J is a moiety containing a basic nitrogen atom but not containing an amino acid residue, preferably amidino, guanidine, amino carboxamido, hydroxylamino, or imidazolyl, or an N-substituted analogue thereof.

Abstract: The present invention relates to halo sulfonyl aryl boronates of the general formula (I): 1

Abstract: In a process for the preparation of ring compounds via a combinatorial synthesis, the reaction procedure is based on a Suzuki coupling, subsequent halo-demetallation and finally a further Suzuki coupling. The Suzuki couplings are each carried out with a boronic acid or a boronic acid ester. The reaction procedure uses provides novel ring compounds and uses novel synthesis units used for this purpose. The novel ring compounds are suitable for use as constituents in liquid-crystalline mixtures.

Abstract: Compounds of the formula (I) 1

Abstract: Compounds of the formula (I) in which Q1 and Q2 are each OH or form a trimeric boric anhydride, Z is CHO, CH2Y, X or a protected aldehyde group, and X is CN, COOH, COCl, CONH2 or C(OR)3, and Y is OH or NH2, and Z is in the o-, m- or p-position to the boronic acid radical, are prepared by a) reacting a compound of the formula (II)  with Mg in the presence of an anthracene compound and, if desired, a transition-metal halide and, if desired, an Mg halide or in the presence of a transition-metal halide and, if desired, an Mg halide, to give the corresponding arylmagnesium chloride, b) reacting the latter with a borate of the formula B(OR′)3 and hydrolyzing the product, with removal of the aldehyde protecting group, c) and, if desired, oxidizing or reducing the free aldehyde group.

Abstract: This invention describes a process for covalently coupling organic compounds which comprises reacting an olefinic compound having a halogen or halogen-like substituent at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base. The invention also describes a process for preparing alkene borate intermediates comprising reacting an olefinic compound having a halogen or halogen-like substituent with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base.

Abstract: In order to provide a method of safely, efficiently, and industrially manufacturing fluoroaryl magnesium halide containing no impurities, such as coloring components, by a relatively gradual reaction compared with the conventional reactions, and a method of readily and efficiently manufacturing a highly-pure fluoroaryl borane derivative, fluoroaryl magnesium halide expressed by General Formula (1): where each of R1-R5 independently represents H, F, a hydrocarbon group, or an alkoxy group, provided that at least three of R1-R5 are fluorine atoms, and Xa represents Cl, Br, or I; is manufactured by reacting, in a solvent containing a chain ether solvent, hydrocarbon magnesium halide expressed by General Formula (2): R6MgXa  (2) where R6 represents a hydrocarbon group, and Xa represents Cl, Br, or I; with fluoroaryl halide expressed by General Formula (3): where each of R1-R5 independently represents H, F, a hydrocarbon group, or an alkoxy group, provided that at

Abstract: Compounds of the formula (I) are prepared by reacting a compound of the formula (V) with a compound of the formula (X) and hydrolyzing the product; or converting the compound of the formula (V) into the hydrazide, and cyclizing and hydrolyzing the latter to give the oxadiazole. para-Oxadiazolylphenylboronic acids are valuable precursors for active ingredients.

Abstract: Novel chiral boron and aluminum hydride complexes, compositions comprising the chiral hydride complexes, and methods for their synthesis and use are described. The novel chiral hydride complexes are of the formulas:MBH.sub.4-n-a (R*).sub.n (R').sub.a ;MBH.sub.2-b (R**) (R').sub.b ;MBH(R***);MBH(R*) (R");MAlH.sub.4-n-a (R*).sub.n (R').sub.a ;MAlH.sub.2-b (R**)(R').sub.b ;MAlH(R***); andMAlH(R*) (R"),whereinM is Na.sup.+, Li.sup.+ or K.sup.+ ;each R* is independently a monodentate chiral ligand;R** is a bidentate chiral ligand;R*** is a tridentate chiral ligand;R' is a monodentate achiral ligand;R" is a bidentate achiral ligand;n is 1-3;a is 0-2; andb is 0-1,with the proviso that n+a.ltoreq.3, and with the further proviso that when R** is S-BINOL, M is not Li.sup.+.

Abstract: Novel compounds which are useful for boron neutron capture therapy (BNCT) are disclosed. The compounds comprise a stable boron-containing group and an aminocycloalkane carboxylic acid group or a boronated acyclic hydrocarbon-linked amino carboxylic acid. Methods for synthesis of the compounds and for use of the compounds in BNCT are disclosed.

Abstract: Sulfur-containing boroester compounds useful as antiwear additives for oleaginous compositions including alicyclic borate thioesters having the general formula (I): ##STR1## wherein R.sub.1 is a hydrocarbyl radical having 4 to 12 carbon atoms, R.sub.2 and R.sub.3 are independently selected from --(OR.sub.4).sub.n SR.sub.1 and --(OR.sub.4).sub.n SR.sub.1 OH; R.sub.4 is a hydrocarbyl radical having 1 to 6 carbon atoms; n is an integer of from 1 to 4; and l and m are independently 0, 1 or 2; thioalkyl-substituted cyclic meta borate esters having the general formula (II): ##STR2## wherein n, R.sub.1 and R.sub.4 are defined as in formula (I); and mixtures of the alicyclic compounds of formula (I) and the cyclic compounds of formula (II).

Abstract: Sulfur-containing boroester compounds useful as antiwear additives for oleaginous compositions including alicyclic borate thioesters having the general formula (I): ##STR1## wherein R.sub.1 is a hydrocarbyl radical having 4 to 12 carbon atoms, R.sub.2 and R.sub.3 are independently selected from --(OR.sub.4).sub.n SR.sub.1 and --(OR.sub.4).sub.n SR.sub.1 OH; R.sub.4 is a hydrocarbyl radical having 1 to 6 carbon atoms; n is an integer of from 1 to 4; and l and m are independently 0, 1 or 2; thioalkyl-substituted cyclic meta borate esters having the general formula (II): ##STR2## wherein n, R.sub.1 and R.sub.4 are defined as in formula (I); and mixtures of the alicyclic compounds of formula (I) and the cyclic compounds of formula (II).

Abstract: Process for the preparation of 2-methoxyimino-2-arylacetic esters of formula (I) in which R is C.sub.1 -C.sub.12 alkyl, which comprises reacting an appropriately substituted boronic acid of general formula (II) or the trimeric form (lII) herein, which is in equilibrium with it, in the presence of a Pd catalyst, with a methoxyiminoacetic ester of formula (IV) in which R is C.sub.1 -C.sub.12 alkyl and X is a leaving group. According to a further process variant, in principle the groups which split off the two reactants may change places. The process can be applied not only to phenyl derivatives but also to larger ring systems (naphthyl, pyridyl, heterocycles).

Abstract: Novel tricyclic compounds of formula I as defined in the specification, a process for their preparation and their use for the preparation of optically active or racemic colchicine and thiocolchicine derivatives.

Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 arid A are defined within.

Abstract: Method of increasing the light output and/or signal:background ratio of light output from a chemiluminescent reaction of a dihydrophthalazinedione, a peroxidase enzyme catalyst and an oxidant, by carrying out the reaction in the presence of an enhancer which is an aromatic organo boron compound. Kits suitable for use in diagnositc assays comprising such enhancers are also described.

Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.

Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.

Abstract: The invention relates to a process for the reaction of fluorinated or chlorinated aromatics with electrophiles at the ortho position relative to the fluorine or chlorine atom, characterized in that a strong base is added to a mixture of the fluorinated or chlorinated aromatic and the electrophile.

Abstract: Mixed alkoxylated alcohol-hydroquinone or alkoxylated alcohol-resorcinol borates are effective multifunctional antioxidants for lubricants.

Abstract: Reduction of friction between metal parts in contact, reductions in corrosion of copper and oxidation of lubricants are made possible by adding to lubricant or liquid fuel a minor amount of a product made by reacting a hydrocarbyl diol, a phenol sulfide and a boron compound.